BioInvent International (BINV.ST) Azione Prezzo
BioInvent International Prezzo
Negli ultimi 19 anni BioInvent International ha aumentato il fatturato del 8,2% all'anno, raggiungendo 226,50 Mio. SEK. Per BioInvent International, il margine netto del -147,0% risulta in aumento rispetto al -1439,1% di alcuni anni fa.
BioInvent International Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
BioInvent International Azione e analisi azionaria
Domande frequenti sull'azione BioInvent International
The business model of BioInvent International AB revolves around the discovery and development of innovative antibody-based immunotherapies. As a biopharmaceutical company, BioInvent focuses on identifying and targeting cancer and immune-mediated inflammatory diseases. Through its strong expertise in antibody research and proprietary antibody library, the company aims to develop novel drug candidates and partner with pharmaceutical companies for further clinical development and commercialization. By leveraging its unique technology platforms, BioInvent strives to provide effective and safe therapies to patients in need, while also generating value for its shareholders and partners.
BioInvent International AB is primarily active in the biotechnology industry.
The main competitors of BioInvent International AB in the market include other biotechnology companies that operate within the same therapeutic area and focus on the development of antibody-based therapeutics. Some notable competitors of BioInvent International AB may include Genmab A/S, MorphoSys AG, and Novartis AG. These competitors also strive to advance innovative solutions for diseases and disorders through research, development, and commercialization of antibody-based drugs. BioInvent International AB positions itself as a leading player in the field, continuously aiming to meet the evolving needs of patients and contribute to the growth of the biotech industry.
BioInvent International AB is a leading biotech company based in Sweden. Founded in 1987, BioInvent focuses on discovering and developing innovative antibody-based drugs for cancer treatment. With a rich history of over three decades, the company has gained expertise and recognition in the field of immuno-oncology. BioInvent collaborates with pharmaceutical partners to advance its proprietary antibody library, F.I.R.S.T™, and to accelerate the development of novel therapeutics. Through its innovative research and development efforts, BioInvent aims to improve patient outcomes and transform the treatment landscape for cancer. The company's commitment to scientific excellence and strategic partnerships has positioned it as a key player in the biopharmaceutical industry.
BioInvent International AB has achieved several significant milestones in its trajectory. The company successfully advanced its lead product candidate, BI-1206, into clinical trials. Furthermore, BioInvent International AB has established strategic collaborations with renowned pharmaceutical companies, including Pfizer and AstraZeneca, facilitating the development of innovative therapeutic antibodies. The company continues to demonstrate its commitment to research and development, expanding its pipeline and enhancing its expertise in the field of immuno-oncology. With a strong focus on strategic partnerships and an impressive track record, BioInvent International AB is well-positioned for future growth and success in the biopharmaceutical industry.
BioInvent International AB is primarily present in Sweden, where it is headquartered. As a biotech company, it focuses on the research and development of novel antibody-based drugs. Its operations encompass a global reach, collaborating with partners and clients across various countries and regions. However, in terms of primary presence and operations, BioInvent International AB is mainly concentrated in Sweden.
BioInvent International AB is a renowned biotech company committed to transforming the treatment of cancer. With a strong corporate philosophy focused on innovation and collaboration, BioInvent strives to deliver ground-breaking antibody-based therapies. The company's core values revolve around scientific excellence, integrity, and patient-centricity. BioInvent harnesses its unique antibody development platform to target and neutralize tumor antigens, leveraging its expertise in antibody engineering and immuno-oncology research. By prioritizing cutting-edge science and strategic partnerships, BioInvent seeks to address unmet medical needs and improve outcomes for cancer patients worldwide.
9 analisti valutano attualmente l’azione BioInvent International: 8 raccomandano l’acquisto, 1 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per BioInvent International ricavi pari a 275,64 Mio. SEK e un utile per azione di -7,03 SEK.
Convertita al tasso di cambio attuale, l’azione BioInvent International quota 0,33 EUR (3,59 SEK).
L’azione BioInvent International (BINV.ST) è quotata su 7 borse, tra cui: London (0H22.L), Frankfurt (BIX0.F), München (BIX0.MU), Düsseldorf (BIX0.DU), Stockholm (BINV.ST).
BioInvent International AB is a biotechnology company based in Lund, Sweden, that focuses on the research and development of antibody therapies. The company's business model is based on the discovery, development, and commercialization of antibodies for the treatment of cancer and other serious diseases. BioInvent operates in three business areas - research and development, therapeutic antibody production and manufacturing, and collaboration and licensing. The company's products include the antibody therapies BI-505 and BI-1206. BI-505 is currently in Phase II studies for the treatment of multiple myeloma patients, and BI-1206 is currently in Phase I studies for the treatment of advanced solid tumors including lung, colorectal, and ovarian cancers. The company's business model is focused on developing innovative antibody therapies that meet the needs of cancer patients, and it works closely with partners to ensure rapid progress in research and development while meeting regulatory requirements. BioInvent is a leading company in the development of antibody therapies and has a promising future in expanding treatment options for cancer patients.
Il attesa fatturato di BioInvent International ammonta a 275,64 Mio. SEK. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di BioInvent International ammonta a -463,28 Mio. SEK. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di BioInvent International è attualmente -0,51. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione BioInvent International.
Il rapporto prezzo/fatturato (P/S) di BioInvent International è attualmente 0,86. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione BioInvent International.
Il Quality Score AlleAktien per BioInvent International è 6/10.
L'ISIN di BioInvent International è SE0015244520. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di BioInvent International è A2QJRW. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di BioInvent International è BINV.ST. Con questo simbolo di borsa vengono negoziate le azioni BioInvent International in borsa.
Azione BioInvent International
Gruppo di pari di BioInvent International
BioInvent International Ticker
BioInvent International FIGI
Altre metriche e analisi di BioInvent International in Deep Dive.
La nostra analisi azionaria dell'azione BioInvent International include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di BioInvent International. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: